NEW YORK (Reuters Health)—For rheumatoid arthritis (RA) patients in stable remission, a panel of inflammatory markers in blood can help predict the odds of relapse when disease-modifying anti-rheumatic drug (DMARD) therapy is tapered, say researchers from Germany. The multibiomarker disease activity (MBDA) score, when combined with anticitrullinated protein antibody (ACPA) testing, can predict relapse in…
People with Schizophrenia at Higher Risk of Osteoporosis
NEW YORK (Reuters Health)—Pooled data indicate that bone mineral density (BMD) is significantly lower in patients with schizophrenia than in healthy controls, according to Taiwanese researchers. Dr. Ping-Tao Tseng tells Reuters Health by email that the “evidence indicates the importance of further screening for the risk of osteoporosis in young-aged schizophrenic patients . . ….
Methotrexate for Ulcerative Colitis Yields Mixed Results
NEW YORK (Reuters Health)—Parenteral methotrexate was no better than placebo for achieving steroid-free remission of ulcerative colitis (UC) in the METEOR trial. But the drug should not be abandoned in all UC patients, researchers say. “Although METEOR failed to reach its primary endpoint, an important secondary endpoint was met. Our study suggests that methotrexate should…
Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…
The Lupus Initiative Launches Cohorts & Partnerships to Reduce Health Disparities & Improve Outcomes
The Lupus Initiative (TLI) of the American College of Rheumatology (ACR) continues its work to reduce the health disparities for people with lupus through multiple, national-level, grant-funded projects, targeting primary care physicians with lupus education to increase appropriate rheumatology referrals and—when necessary, appropriate and effective—distance-managed care. Since 2009, the ACR has received funding through the…
A Healthy Skepticism: Researchers Evaluate CNS Manifestations of Rheumatic Disease
SAN FRANCISCO—Let’s say your radiologist comes to you and says that an angiogram gives a diagnosis of CNS vasculitis on four patients, all with acute onset of headache and stroke: One is a 25-year-old woman who is three months pregnant. Another is a 50-year-old man using excessive doses of nasal decongestants. Another is a 40-year-old…
NIH-Funded Trials Dip While Industry Trials Are on the Rise
(Reuters Health)—Every year since 2006 in the U.S., the number of clinical trials funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows. Analyzing the ClinicalTrials.gov database, researchers found that after trial registration became a requirement for publication in major scientific…
Combo Drug for Arthritis & Hypertension Meets Goal in Phase 3 Study
(Reuters)—Kitov Pharmaceuticals Holdings Ltd. said on Tuesday its lead drug, KIT-302, met the main goal of a late-stage study, reducing pain without increasing the risk of heart diseases in patients with osteoarthritis. Israel-based Kitov says its drug does not need to be labeled with health warnings, but will instead say it reduces the risk of…
New SLE Drug May Allow Patients to Reduce Steroid Use
In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…
The ACR Announces Advocacy Priorities for 2016
After its December meeting, the ACR Government Affairs Committee has determined the federal and state issues the College will focus its advocacy efforts on in 2016. These issues include ensuring implementation of the Medicare Access & CHIP Reauthorization Act of 2015 protects rheumatologists, creating an arthritis research program at the Department of Defense and more…
- « Previous Page
- 1
- …
- 274
- 275
- 276
- 277
- 278
- …
- 322
- Next Page »